Madrigal Pharmaceuticals (MDGL) Stock Statistics & Valuation Metrics

Madrigal Pharmaceuticals has a market cap or net worth of $9.94B. The enterprise value is $15.16B.

Market Cap

$9.94B

Enterprise Value

$15.16B

Madrigal Pharmaceuticals has 23,104,126 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding

23,104,126

Owned by Insiders

18.08%

Owned by Institutions

37.87%

Madrigal Pharmaceuticals’s return on equity (ROE) is -0.48 and return on invested capital (ROIC) is -31.58%.

Return on Equity (ROE)

-0.48

Return on Assets (ROA)

-0.23

Return on Invested Capital (ROIC)

-31.58%

Return on Capital Employed (ROCE)

-0.32

Revenue Per Employee

1.05M

Profits Per Employee

-315.06K

Employee Count

915

Asset Turnover

0.76

Inventory Turnover

0.75

The current PE Ratio of Madrigal Pharmaceuticals is -33.39. Madrigal Pharmaceuticals’s PEG ratio is 96.72.

PE Ratio

-33.39

PS Ratio

7.74

PB Ratio

23.95

Price to FCF

-48.20

Price to Operating Cash Flow

-63.44

PEG Ratio

96.72

In the last 12 months, Madrigal Pharmaceuticals had revenue of 958.40M and earned -288.28M in profits. Earnings per share was -12.85.

Revenue

958.40M

Gross Profit

902.25M

Operating Income

-300.10M

Pretax Income

-288.28M

Net Income

-288.28M

EBITDA

-264.47M

Earnings Per Share (EPS)

-12.85

In the last 12 months, operating cash flow was -197.72M and capital expenditures -8.57M, giving a free cash flow of -206.28M billion.

Operating Cash Flow

-197.72M

Free Cash Flow

-206.28M

Free Cash Flow per Share

-7.08

Madrigal Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share

―

Dividend Yield

―

Payout Ratio

N/A

Free Cash Flow Yield

-2.07%

Earnings Yield

-2.59%

Beta

0.27

52-Week Price Change

0.66%

50-Day Moving Average

499.15

200-Day Moving Average

500.35

Relative Strength Index (RSI)

29.50

Average Volume (3m)

270.01K

Madrigal Pharmaceuticals upcoming earnings date is Nov 03, 2026, Before Open (Not Confirmed).

Last Earnings Date

Jul 30, 2026

Next Earnings Date

Nov 03, 2026

Ex-Dividend Date

―

Madrigal Pharmaceuticals as a current ratio of 4.01, with Debt / Equity ratio of 58.80%

Current Ratio

4.01

Quick Ratio

3.77

Debt to Market Cap

0.03

Net Debt to EBITDA

-0.59

Interest Coverage Ratio

-13.45

In the past 12 months, Madrigal Pharmaceuticals has paid 0 in taxes.

Income Tax

0

Effective Tax Rate

0.00

Madrigal Pharmaceuticals EV to EBITDA ratio is -34.23, with an EV/FCF ratio of -48.47.

EV to Sales

7.79

EV to EBITDA

-34.23

EV to Free Cash Flow

-48.47

EV to Operating Cash Flow

-50.57

Madrigal Pharmaceuticals has $838.75M in cash and marketable securities with $347.75M in debt, giving a net cash position of $491.00M billion.

Cash & Marketable Securities

$838.75M

Total Debt

$347.75M

Net Cash

$491.00M

Net Cash Per Share

$21.25

Tangible Book Value Per Share

$17.72

Gross margin is 91.48%, with operating margin of -25.13%, and net profit margin of -25.32%.

Gross Margin

91.48%

Operating Margin

-25.13%

Pretax Margin

-25.32%

Net Profit Margin

-25.32%

EBITDA Margin

-22.75%

EBIT Margin

-22.87%

The average price target for Madrigal Pharmaceuticals is $686.78, which is 11.43% higher than the current price. The consensus rating is Strong Buy

Price Target

$686.78

Price Target Upside

59.58% Upside

Analyst Consensus

Strong Buy

Analyst Count

9

Revenue Growth Forecast

149.04%

EPS Growth Forecast

-0.28%

Smart Score

2

AI Score

49